The prevalence of diabetes is expected to rise together with an increase in morbidity and a reduction in life expectancy. A leading cause of death is cardiovascular disease, and hypertension and diabetes are additive risk factors for this complication. Selected treatment options should neither increase cardiovascular risk in patients with diabetes, nor increase risk of hyperglycaemia in patients with hypertension. The efficacy of present antihyperglycaemic agents is limited and new therapies, such as incretin-targeted agents, are under development. Even though most patients do not achieve glycated haemoglobin targets, trial data show that such interventions reduce the incidence of macrovascular events; however, intensive lowering may be detrimental in patients with existing cardiovascular disease. Currently available oral drugs do not address the key driver of type 2 diabetes--loss of functional beta-cell mass. In the future, new oral treatments must improve this, whilst providing durable blood glucose control and long-term tolerability.

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? / Giugliano, D; Standl, E; Vilsbøll, T; Betteridge, J; Bonadonna, Riccardo; Campbell, Iw; Schernthaner, Gh; Staels, B; Trichopoulou, A; Farinaro, E.. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 46:(2009), pp. 173-181.

Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings?

BONADONNA, Riccardo;
2009-01-01

Abstract

The prevalence of diabetes is expected to rise together with an increase in morbidity and a reduction in life expectancy. A leading cause of death is cardiovascular disease, and hypertension and diabetes are additive risk factors for this complication. Selected treatment options should neither increase cardiovascular risk in patients with diabetes, nor increase risk of hyperglycaemia in patients with hypertension. The efficacy of present antihyperglycaemic agents is limited and new therapies, such as incretin-targeted agents, are under development. Even though most patients do not achieve glycated haemoglobin targets, trial data show that such interventions reduce the incidence of macrovascular events; however, intensive lowering may be detrimental in patients with existing cardiovascular disease. Currently available oral drugs do not address the key driver of type 2 diabetes--loss of functional beta-cell mass. In the future, new oral treatments must improve this, whilst providing durable blood glucose control and long-term tolerability.
2009
Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? / Giugliano, D; Standl, E; Vilsbøll, T; Betteridge, J; Bonadonna, Riccardo; Campbell, Iw; Schernthaner, Gh; Staels, B; Trichopoulou, A; Farinaro, E.. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 46:(2009), pp. 173-181.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2762617
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 22
social impact